You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥(02142.HK)曾飆近四成 與科倫博泰生物醫藥簽兩款產品分成協議
阿思達克 12-23 14:04
和鉑醫藥(02142.HK)公布,全資子公司諾納生物(蘇州)與四川科倫博泰生物醫藥股份簽署兩項補充協議,其中諾納生物與科倫博泰一致同意科倫博泰有權就雙方共同開發的兩款ADC產品許可給被許可第三方。和鉑醫藥午後股價曾升39.6%,高見2.54元,現升33.5%,報2.43元。成交841.1萬股,成交額1,889.4萬元。 根據補充協議,諾納生物有權獲得源於該兩款產品所得款項的30%。產品1為諾納生物許可科倫博泰授權第三方項目,諾納生物有權獲得產品1首付款、里程碑付款和分級特許權使用費的30%;產品1首付款為3,000萬美元,諾納生物有權獲得其中的30%。 產品2為諾納生物許可科倫博泰與第三方合作開發項目,諾納生物有權獲得產品2首付款、里程碑付款和分級特許權使用費的30%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account